Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Adicet Bio develops off-the-shelf immune cell therapies to treat cancer and autoimmune diseases.
Adicet Bio is a clinical-stage biotech company engineering a new kind of cancer and autoimmune drug: gamma delta T cells, a rare type of immune cell that acts like a first responder. The company harvests these cells from healthy donors, edits them in the lab so they hunt specific targets, and turns them into a frozen, ready-to-infuse product. That "off-the-shelf" design is the whole point. The alternative, CAR-T therapy, is made from each patient's own cells鈥攁 slow, expensive, one-patient-at-a-time manufacturing process. Adicet wants a vial on the shelf instead.
Its lead program is a drug called ADI-001, an allogeneic gamma delta T cell therapy aimed at CD20, a protein found on certain lymphoma cells and on the B cells that misfire in autoimmune disease. The company is running it in B-cell blood cancers and in autoimmune conditions like lupus, betting that the same cell can be sold into two enormous markets. Gamma delta T cells are an attractive chassis because they don't seem to trigger severe graft-versus-host disease, the immune attack on the patient's own body that makes donor-cell therapies risky. Adicet also has earlier-stage programs it describes as "armored" cell therapies鈥攃ells engineered to withstand the hostile environment inside a tumor. This is a money-burning research operation, not a product business. Adicet earns essentially no revenue; it funds itself through cash reserves, equity raises, and partnerships, and investors are effectively paying for clinical trial results years before any drug could be approved. That makes the company brutally dependent on data. Positive trial results can send the stock soaring and open the door to financing or a pharma partnership; a safety scare or a failed study can do the reverse. The broader cell-therapy field is crowded and volatile, and several allogeneic players have stumbled, which raises the bar for Adicet's clinical proof.
The company is based in the Boston area, a hub for biotech talent and cell-therapy manufacturing. Its central bet is a genuine scientific fork in the road: if donor-derived gamma delta T cells prove safe and effective in repeat doses, the company could offer something cheaper and more scalable than bespoke CAR-T. If the data don't hold up, the technology stays a promising idea. For now, Adicet is a science project with a stock ticker鈥攚orth understanding, but not yet a business that makes money.
Saved answer 路 last researched 15 Nov 2026